Medscape Conference Coverage, based on selected sessions at the:

American Headache Society (AHS) 50th Annual Scientific Meeting

June 26 - 29, 2008; Boston, Massachusetts

This activity is not sanctioned by, nor a part of, the American Headache Society. Conference news does not receive grant support and is produced independently.

Conference News

  • Lack of Access to Specialty Care and Research Funds Plague Headache

    Two new studies suggest that US patients with headache lack access to specialty care and that the field is suffering from a serious shortage of research funding.
    Medscape Medical News, July 10, 2008
  • Topiramate Safe, Effective for Migraine Prophylaxis in Adolescents

    The first successful randomized controlled trial of migraine prevention in adolescents the United States has shown topiramate reduces migraine frequency and severity in children aged 12 to 17 years.
    Medscape Medical News, July 10, 2008
  • Vitamin D Deficiency and Chronic Migraine

    New research showing that vitamin D deficiency is common in patients with chronic migraine suggests that this patient group, like other vitamin D deficient populations, is at increased risk for cardiovascular disease, malignancy, and other serious illnesses that have been linked to low levels of this vitamin.
    Medscape Medical News, July 7, 2008
  • Experimental Portable Device Shows Promise in Treating Migraine with Aura

    Early treatment with transcranial magnetic stimulation using an experimental, portable handheld device appears to be safe and effective in the treatment of acute migraine with aura.
    Medscape Medical News, July 3, 2008
  • Migraineurs With Comorbid Pain Disorders More Likely to Have Suffered Child

    New research suggests migraineurs who have suffered childhood abuse are much more likely than their counterparts who have not been abused to have comorbid pain conditions, including arthritis, irritable bowel syndrome, and fibromyalgia.
    Medscape Medical News, July 2, 2008
  • Experimental Agent for Migraine Pain, Symptoms

    An investigational oral migraine medication is effective in the treatment of acute moderate to severe attacks and associated symptoms, without the direct vasoconstrictive effects typically associated with triptans.
    Medscape Medical News, June 30, 2008
Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Headache Society. These materials and the related activity are not sanctioned by the American Headache Society or the commercial supporter of the conference and do not constitute an official part of that conference.